Clinical optimization of ultrasonic drug delivery technologies for underserved minority US veterans in chronic pain

Ended Project Grant Awarded Last action

Award ID
R44MD015912
Recipient
Awarding agency
Obligated
$19,045,661

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Place of performance
Trumbull, CT 06611, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Narcotic use in pain management of underserved minority populations and minority united states veterans has played a major role in the ongoing opioid crisis. According to the NIH, veterans are more susceptible to opioid addiction and are 40% more likely to suffer from severe chronic joint pain then non-veterans. Over the next decade, the percentage of minority veterans will increase from 23% to 34% and is expected to rise. This shift of racial and ethnic minorities directly correlates to the growing demographics of minority active-duty soldiers that make up over 40% of our nation's military forces. The federal government considers the 18.2 million veteran and 42 million non-veteran minority americans to be "potentially vulnerable patient populations" with health disparities particularly related to joint diseases care. Osteoarthritis (OA) is one of the most common of these joint diseases affecting the entire US population, and of considerably higher 19-fold incidence and prevalence in the service- disabled veteran population. Although the disease itself does not appear to occur more frequently in minorities, its effects and progression are more severe. This is especially true among minorities with arthritis, 36.7% of black patients and 35.5% of hispanic patients reported severe joint pain compared to only 23.0% of non-hispanic whites. The economic burden of veterans with OA is estimated to approach or exceed $60 billion annually due to longer life expectancies. Arthritis is also a significant economic and health burden in the united states at large which is estimated to exceed $394 billion in healthcare costs by 2030. In our sbir heal phase i, we developed a wireless long-duration low-intensity ultrasound nsaid-enhanced (2.5% diclofenac) sonophoresis system for use by the underserved OA population. We first demonstrated that the sonophoresis technology could increase tissue penetration of nsaids by 3.8X compared to standard of care (p

Transactions

Action Obligated Date
Amendment $0
Amendment $145,736
Amendment $1,311,907
Amendment $1,311,907
Amendment $1,311,907
Amendment $1,311,907
Amendment $6,288
Amendment $6,288
Amendment $6,288
Amendment $157,222
Amendment $157,222
Amendment $157,222
Amendment $157,222
Amendment $1,414,985
Amendment $1,414,985
Amendment $1,414,985
Amendment $1,414,985
Amendment $1,414,985
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,482,405
Amendment $1,482,405
Amendment $1,482,405
Original award $1,482,405
Show all 28

Quick answers

Who received award R44MD015912?

R44MD015912 was awarded to Zetroz Systems LLC by National Institute for Minority Health and Health Disparities (National Institutes of Health) on September 14, 2020.

How much is award R44MD015912 worth?

$19,045,661 has been obligated on R44MD015912.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login